Construction of the plant will commence in 2025 with first production expected to be in 2027
Growth markets revenue increased by 44 YoY to Rs. 812 crore
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Subscribe To Our Newsletter & Stay Updated
